Picture1.png
Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease
October 07, 2021 08:00 ET | Acumen Pharmaceuticals, Inc.
ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Enrollment of early Alzheimer’s...
effector.jpg
eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference
September 16, 2021 08:00 ET | eFFECTOR Therapeutics, Inc.
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...
Codex DNA Releases Full-Length Synthetic Genome for Highly Infectious SARS-CoV-2 Delta Variant
September 01, 2021 16:15 ET | Codex
San Diego, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the release of its first full-length...
Logo.png
PetVivo Holdings, Inc. to Exhibit at Western Veterinary Conference in Las Vegas, Nevada
August 30, 2021 08:00 ET | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Aug. 30, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative...
ibn-iw-globe-2.png
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Kelsey Ramsden, Co-Founder & CEO of Mind Cure Health Inc.
August 19, 2021 08:17 ET | InvestorBrandNetwork (IBN)
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
Histogen logo 300.jpg
Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021
July 28, 2021 16:05 ET | Histogen Inc
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Healthtech Solutions, Inc. Announces Appointment of Paul Mann to the Board of Directors
July 20, 2021 16:30 ET | Healthtech Solutions, Inc.
NEW YORK, July 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Healthtech Solutions, Inc. (OTC: HLTT) (“Healthtech” or the “Company”), an innovative portfolio-model life sciences company focused on...
arbor-logo-tree-color.png
Arbor Strengthens Focus on Therapeutics with Key Additions to Leadership Team
July 20, 2021 08:00 ET | Arbor Biotechnologies Inc
- Pam Stetkiewicz, Ph.D., Appointed Chief Operating Officer - Kathryn McCabe, Ph.D., Named SVP, Head of Business Development CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- Arbor...
logo.gif
Auris Medical Announces Launch of New Corporate Website
July 16, 2021 09:00 ET | Auris Medical AG
Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection,...
Picture1.png
Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
June 30, 2021 22:44 ET | Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a...